ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China.PLoS medicine · 2025Trial
- Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials.Molecular oncology · 2025Trial
- Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer.Discover oncology · 2026Article
- Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study.Annals of surgical oncology · 2026Article
- Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy.JAMA network open · 2026Article
- Unresectable stage III non-small-cell lung cancer: state of the art and challenges.Nature reviews. Clinical oncology · 2026Review
- Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- The Progression Patterns and Subsequent Treatments of First-Line Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Thoracic cancer · 2025Article
- Article
- Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Diagnostic and prognostic roles of circulating EVs circ_PPAPDC1A in ICIs resistance in NSCLC.NPJ precision oncology · 2025Article
- Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study.Cancer immunology, immunotherapy : CII · 2025Observational
- Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer.Frontiers in immunology · 2025Article
- Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.JTO clinical and research reports · 2024Review
- Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.JTO clinical and research reports · 2024Article
- Article
- Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Controlled Chaos: Parsing Acquired Immunoresistance in Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.Translational lung cancer research · 2024Article
- Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse.Cancers · 2024Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 2 institutions in 4 countries.
Funding
Abstract
purposeClinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. EXPERIMENTAL
designAll cases of metastatic lung cancer treated with PD-(L)1 blockade at Memorial Sloan Kettering were reviewed. In acquired resistance (complete/partial response per RECIST, followed by progression), clinical patterns were distinguished as oligo (OligoAR ≤ 3 lesions of disease progression) or systemic (sAR). We analyzed the relationships between patient characteristics, burden/location of disease, outcomes, and efficacy of therapeutic interventions.
resultsOf 1,536 patients, 312 (20%) had an initial response and 143 developed AR (9% overall, 46% of responders). OligoAR was the most common pattern (80/143, 56%). Baseline tumor mutational burden, depth of response, and duration of response were significantly increased in oligoAR compared with sAR (P < 0.001, P = 0.03, P = 0.04, respectively), whereas baseline PD-L1 and tumor burden were similar. Post-progression, oligoAR was associated with improved overall survival (median 28 months vs. 10 months, P < 0.001) compared with sAR. Within oligoAR, post-progression survival was greater among patients treated with locally-directed therapy (e.g., radiation, surgery; HR, 0.41; P = 0.039). Fifty-eight percent of patients with oligoAR treated with locally-directed therapy alone are progression-free at last follow-up (median 16 months), including 13 patients who are progression-free more than 2 years after local therapy.
conclusionsOligoAR is a common and distinct pattern of acquired resistance to PD-(L)1 blockade compared with sAR. OligoAR is associated with improved post-progression survival and some cases can be effectively managed with local therapies with durable benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.